Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance.
Geretti AM, White E, Orkin C, Tostevin A, Tilston P, Chadwick D, Leen C, Sabin C, Dunn DT; UK HIV Drug Resistance Database and UK CHIC Study. Geretti AM, et al. Among authors: dunn dt. J Antimicrob Chemother. 2019 Mar 1;74(3):746-753. doi: 10.1093/jac/dky468. J Antimicrob Chemother. 2019. PMID: 30544247 Free PMC article.
A randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8) trial.
Green H, Gibb DM, Compagnucci A, Giacomet V, de Rossi A, Harper L, Saïdi Y, Castelli-Gattinara G, Pillay D, Babiker AG, Aboulker JP, Lyall H, Bacheler LT, Walker AS, Debré M, Rosso R, Burger DM, Della Negra M, Dunn DT, Giaquinto C; Paediatric European Network for the Treatment of AIDS. Green H, et al. Among authors: dunn dt. Antivir Ther. 2006;11(7):857-67. Antivir Ther. 2006. PMID: 17302248 Clinical Trial.
Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children.
HIV Paediatric Prognostic Markers Collaborative Study; Boyd K, Dunn DT, Castro H, Gibb DM, Duong T, Aboulker JP, Bulterys M, Cortina-Borja M, Gabiano C, Galli L, Giaquinto C, Harris DR, HugheS M, McKinney R, Mofenson L, Moye J, Newell ML, Pahwa S, Palumbo P, Rudin C, Sharland M, Shearer W, Thompson B, Tookey P. HIV Paediatric Prognostic Markers Collaborative Study, et al. Among authors: dunn dt. AIDS. 2010 May 15;24(8):1213-7. doi: 10.1097/QAD.0b013e3283389f41. AIDS. 2010. PMID: 20386428
Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy?
Gompels M, Dunn DT, Phillips A, Dooley D, De Burgh Thomas A, Anderson J, Post F, Pillay D, Gazzard B, Hill T, Johnson M, Gilson R, Bansi L, Easterbrook P, Fisher M, Walsh J, Orkin C, Ainsworth J, Leen C, Sabin C; UK Collaborative HIV Cohort (UK CHIC) Study (Appendix). Gompels M, et al. Among authors: dunn dt. J Infect Dis. 2012 Feb 15;205(4):540-7. doi: 10.1093/infdis/jir380. J Infect Dis. 2012. PMID: 22279171
Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial.
Paton NI, Goodall RL, Dunn DT, Franzen S, Collaco-Moraes Y, Gazzard BG, Williams IG, Fisher MJ, Winston A, Fox J, Orkin C, Herieka EA, Ainsworth JG, Post FA, Wansbrough-Jones M, Kelleher P; Hydroxychloroquine Trial Team. Paton NI, et al. Among authors: dunn dt. JAMA. 2012 Jul 25;308(4):353-61. doi: 10.1001/jama.2012.6936. JAMA. 2012. PMID: 22820788 Free PMC article. Clinical Trial.
132 results